Sandbox Reserved 1227
From Proteopedia
(Difference between revisions)
Line 4: | Line 4: | ||
== Function == | == Function == | ||
- | Mdm2 is an E3 ubiquitin ligase that ubiquitylates and binds the transcriptional activation domain of p53 | + | Mdm2 is an E3 ubiquitin ligase that ubiquitylates and binds the transcriptional activation domain of p53 which signals for degradation of the cell. MDM2 and the closely related MDM4 are two of the main inhibitory proteins of the p53 pathway. The p53 pathway is activated when the cell is distressed and needs to be broken down. The p53 pathway leads to the ceasing of proliferation of the cell, or cell death. The expression of MDM2 is activated by p53 by an auto regulatory feedback loop<ref>Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296-9. doi:http://dx.doi.org/10.1038/387296a0</ref>. Too much MDM2 can turn off the p53 pathway, allowing the cell to grow uncontrollably, allowing for tumor growth. The association between p53 and the MDM proteins can be seen in <scene name='75/750276/Mdm4-p53_interaction/1'>p53-MDM4 interaction</scene>. On the other hand, if MDM2 or MDM4 is under regulated, p53 will overwork, causing cell death more often and earlier on than necessary.<ref>Eischen, C. M., & Lozano, G. (2014). The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Human Mutation, 35(6), 728–737. http://doi.org/10.1002/humu.22524</ref> |
== Relevance == | == Relevance == | ||
- | Often, the p53 pathway is compromised due to the over expression of proteins such as MDM2 or MDM4. This over expression can lead to decreased activity of p53 which allows the cell to proliferate even when the body signals it to be destroyed. This is thought to be one of the lead causes of tumor progression<sup>[1]</sup>. Data involving MDM2 and the SNP285 polymorphism within its promotor region have been researched, and this region has been shown to be significantly linked to a decreased cancer risk<ref>Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.</ref>. It is believed that further MDM2 research and therapy could possibly lead to an anticancer strategy <ref>Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.</ref>. However, the cancer cells are very good at acquiring mutations to allow them to survive even in the presence of these drugs. Also, adverse side effects have been noted when trying to use these anti-cancer strategies<sup>[ | + | Often, the p53 pathway is compromised due to the over expression of proteins such as MDM2 or MDM4. This over expression can lead to decreased activity of p53 which allows the cell to proliferate even when the body signals it to be destroyed. This is thought to be one of the lead causes of tumor progression<sup>[2]</sup>. Recent data has also shown increased MDM2 levels associated with decreased p53 levels, meaning that MDM2 could potentially cause complete degradation of p53<sup>[1]</sup>. Data involving MDM2 and the SNP285 polymorphism within its promotor region have been researched, and this region has been shown to be significantly linked to a decreased cancer risk<ref>Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.</ref>. It is believed that further MDM2 research and therapy could possibly lead to an anticancer strategy <ref>Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.</ref>. However, the cancer cells are very good at acquiring mutations to allow them to survive even in the presence of these drugs. Also, adverse side effects have been noted when trying to use these anti-cancer strategies<sup>[2]</sup>. |
== Structural highlights == | == Structural highlights == |
Revision as of 02:30, 27 April 2017
This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
MDM2
|
References
- ↑ Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296-9. doi:http://dx.doi.org/10.1038/387296a0
- ↑ Eischen, C. M., & Lozano, G. (2014). The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Human Mutation, 35(6), 728–737. http://doi.org/10.1002/humu.22524
- ↑ Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.
- ↑ Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.
- ↑ Ciemny, M. P., Debinski, A., Paczkowska, M., Kolinski, A., Kurcinski, M., & Kmiecik, S. (2016). Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction. Scientific Reports, 6, 37532. http://doi.org/10.1038/srep37532.